FiercePharma, by Carly Helfand, Jan 28, 2019 AstraZeneca has struck a deal with UPMC Health Plan (USA) that links reimbursement for the blood thinner, which is approved to cut the risk of death or a second heart attack in people who have already had one, to patients’ cardiovascular outcomes—the usual trade-off for a value-based deal. But […]
FiercePharma, by Angus Liu, Jan 29, 2019 Pfizer has launched China’s first pay-for-performance program in oncology with its blockbuster breast cancer drug Ibrance, China Daily reported. Under the new program, called Bo’ai Xin’an, Pfizer promises reimbursement of up to 33.5% of Ibrance costs if an enrolled patient’s disease progresses within four months. The U.S. pharma set […]
FiercePharma / by Eric Sagonowsky onMay 3, 2017 On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim. Through the first-of-its-kind contract, if a patient on Repatha has a heart attack or stroke, the drugmaker will provide a full refund. As the […]
by Amirah Al Idrus in FierceBiotech on Apr 19, 2017 Verily’s Project Baseline, which aims to better understand what it means to be healthy and how health transitions to disease, has launched in partnership with Duke University and Stanford University. The study will collect health data from 10,000 participants over four years. The study will […]
18. Nov. 2015 in PharmaTimes The National Institute for Health and Care Excellence has turned down Amgen’s Repatha – the world’s first approved PCSK9 inhibitor – as an option for people with high cholesterol and mixed dyslipidaemia. Key reasons for the negative decision were: (1) no long-term outcomes data and thus, the question of whether […]
FierceHealthPayer, Feb 25, 2015 By Dina Overland Although almost 25 state programs employ higher copays for emergency department visits in an effort to decrease ED use, charging more when Medicaid recipients go to the ED may not be effective, reported Stateline. At least one multistate study determined that charging higher copays doesn’t necessarily lower ED […]
Pharmatimes Online. 15 May 2013 The pharmaceutical industry has now entered the Outcomes Era where compounds must supply convincing evidence of a new drug’s value, with proof of the best possible health outcomes and additional benefits if it is to achieve attractive price and reimbursement levels, says new research.As many as 60% of pharmaceutical executives […]